Marker Therapeutics, Inc.
MRKR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.07 | 0.13 | 0.02 | 0.17 |
| FCF Yield | -39.07% | -33.93% | -143.74% | -41.83% |
| EV / EBITDA | -1.93 | -2.96 | -1.12 | -1.16 |
| Quality | ||||
| ROIC | -60.19% | -103.79% | -72.71% | -69.90% |
| Gross Margin | -104.34% | -214.62% | 59.12% | -154.67% |
| Cash Conversion Ratio | 1.02 | 1.17 | 1.36 | 0.65 |
| Growth | ||||
| Revenue 3-Year CAGR | 23.33% | 38.67% | 95.98% | 79.92% |
| Free Cash Flow Growth | 33.64% | 48.49% | -4.95% | -3.84% |
| Safety | ||||
| Net Debt / EBITDA | 4.24 | 1.34 | 0.26 | 0.84 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | -10.54 | 0.00 | 0.00 |
| Cash Conversion Cycle | 101.07 | 45.01 | -11.84 | -593.53 |